TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQ: EVGN), an agri-tech (agricultural technology) and bio-tech company with a computational predictive biological platform technology that it leverages to five relatively early-stage subsidiaries: three of which have reached the commercialization phase.

Today's article is titled, “Evogene - A Company With Valuable Assets Trading At Zero Enterprise Value.”

Key Highlights include:

• Trading at cash: The company's market cap is around $30 million, trading at around cash levels since mid-2022, following a very sharp 90%+ fall from its peak of around $9.50 in February 2021.

• The subsidiaries have real value, as evidenced by external investments from professional VC funds: investment into subsidiaries, suggest that Evogene's subsidiaries, Biomica and Lavie Bio, are each worth well more, than the market valuation of Evogene itself.

• Casterra, a subsidiary focused on genetically advanced castor seeds for oil production, has the highest potential for significant value creation in the short-term and just announced a large $9 million initial purchase order from a major oil company for seeds for growing biofuel.

• Evogene's technology platform, the Computational Predictive Biology platform (CPB), has significant value due to the company's extensive investment in research and development over two decades, and partnerships with leading ag-companies.

• The conservative valuation of Evogene and its subsidiaries, along with its technology, suggests a value well above $224 million, or over $5 per share, indicating a potential upside of over 6X. Recent positive developments, such as sales of Casterra seeds and investments in subsidiaries, indicate increasing cash flow for Evogene, reducing the risk of capital depletion.

Read the fuill article here.

Previous artricles in the series include:

Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries

Evogene Offers An Excellent Risk/Reward Ratio

More By This Newswire:

TalkMarkets Announces Company Spotlight Featuring Adamas One

Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital

RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

Originallay published at TalkMakets. TalkMarkets is a financial site that customizes, optimizes, and socializes content to ensure a personalized experience. For more information, please visit www.TalkMarkets.com

Contact Details

TalkMarkets

ir@talkmarkets.com